<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395222</url>
  </required_header>
  <id_info>
    <org_study_id>19-08020738</org_study_id>
    <nct_id>NCT04395222</nct_id>
  </id_info>
  <brief_title>Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation</brief_title>
  <official_title>A Prospective Study of Tocilizumab for the Prevention of Graft Failure and Graft-versus-Host Disease in Haplo-Cord Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of reducing and ultimately eliminating
      anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and
      replacing it with tocilizumab, an IL-6 receptor monoclonal antibody, to improve immune
      reconstitution and reduce relapse while preserving low rates of graft failure and graft
      versus host disease (GVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective phase II non-inferiority study investigating tocilizumab as a
      potential alternative to anti-thymocyte globulin (ATG) in haplo-cord transplantation. It is a
      single-center study based at Weill Cornell Medicine/NewYork Presbyterian Hospital.

      The hypothesis is that tocilizumab is a safe and effective alternative to ATG in haplo-cord
      transplantation, facilitating transient engraftment of the haplo-identical stem cell graft
      without prolonged neutropenia or second nadir prior to durable cord engraftment while also
      preventing graft versus host disease (GVHD).

      This study plans to enroll patients with hematologic malignancies in need of alternate donor
      transplant. All subjects will be conditioned with fludarabine, melphalan and total body
      irradiation (TBI), followed by a single dose of tocilizumab 8 mg/kg on Day -1. Patients will
      be enrolled into 4 successive cohorts, initially administering the current standard 3 doses
      of ATG 1.5 mg/kg (total 4.5 mg/kg). In the absence of safety signals, we will drop one dose
      of ATG in successive cohorts until the drug ultimately has been eliminated.

      The primary endpoint of the study is successful haplo-derived neutrophil engraftment.
      Treatment will only be of interest if there is evidence that this rate is greater than 60%.
      If there are 4 or fewer successes, that dose group will be deemed unacceptable and the next
      higher ATG dose for which there were 5 or more success will be expanded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with successful haplo-derived neutrophil engraftment</measure>
    <time_frame>21 days post-transplant</time_frame>
    <description>This is defined as:
Achieve an absolute neutrophil count (ANC) of 500 cells/microL for three consecutive days with the first on or prior to Day +21 post-transplant, AND
Absence of a second nadir - a drop in the ANC to &lt;300 cells/microL for five consecutive days - after initial neutrophil recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Time elapsed between Day 0 and progression of the underlying malignancy for which the transplant was performed, assessed up to 5 years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Time elapsed between Day 0 and death from any cause, assessed up to 5 years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-Related Mortality</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Proportion of deaths which cannot be explained by persistence, relapse or progression of the underlying malignancy once the preparative regimen starts, assessed up to 5 years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Platelet Engraftment Success</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>Proportion of patients who successfully achieve platelet engraftment, defined as a platelet count of &gt;20k/microL for three consecutive days without transfusion support for seven consecutive days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Failure of the Haplo-Graft</measure>
    <time_frame>21 days post-transplant</time_frame>
    <description>Proportion of patients with a failed haplo-graft, defined as the absence of neutrophil engraftment by Day +21 or a drop in the absolute neutrophil count to &lt;0.3 cells/microL for five consecutive days occurring after initial neutrophil engraftment within the first 3 weeks post-transplantation (second nadir)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Acute Graft-versus-Host Disease</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Proportion of patients who develop acute graft-versus-host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Chronic Graft-versus-Host Disease</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Proportion of patients who develop chronic graft-versus-host disease</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hematologic Malignancy</condition>
  <condition>Bone Marrow Transplant</condition>
  <arm_group>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen.
Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)
Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.
Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.
Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen.
Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)
Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.
Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.
Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen.
Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)
Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.
Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.
Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG Group IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)
Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.
Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.
Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_label>ATG Group IV</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_label>ATG Group IV</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_label>ATG Group IV</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin (rabbit)</intervention_name>
    <description>Anti-thymocyte globulin (ATG) 1.5 mg/kg</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_label>ATG Group IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have a confirmed diagnosis of one of the following:

               1. Relapsed or refractory acute leukemia (myeloid or lymphoid)

               2. Acute leukemia in first remission at high-risk for recurrence

               3. Chronic myelogenous leukemia in chronic, accelerated phase or blast-crisis

               4. Myelodysplastic syndromes

               5. Chronic myeloproliferative disease

               6. Recurrent, refractory or high-risk malignant lymphoma

               7. Chronic lymphocytic leukemia, relapsed or with poor prognostic features

               8. Multiple myeloma

               9. Other hematological disorder in need of allogeneic transplant (e.g. blastoid
                  dendritic cell neoplasm)

          2. Age ≥ 18 years.

          3. Likely to benefit from allogeneic transplant in the opinion of the transplant
             physician.

          4. An HLA-identical related or unrelated donor cannot be identified within an appropriate
             time frame.

          5. Karnofsky Performance Status (KPS) of ≥ 70%.

          6. Acceptable organ function as defined below:

               1. Serum bilirubin: &lt;2.0 mg/dL

               2. ALT (SGPT) &lt;3x upper limit of normal (ULN)

               3. Creatinine Clearance: &gt;50 mL/min/1.73m2 (eGFR as estimated by the modified MDRD
                  equation)

               4. Left ventricular ejection fraction &gt;40%

               5. Pulmonary diffusion capacity &gt;40% predicted

          7. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Life expectancy is severely limited by concomitant illness or uncontrolled infection.

          2. Evidence of chronic active hepatitis or cirrhosis

          3. Uncontrolled HIV disease.

          4. Pregnancy or lactation.

          5. History of complicated diverticulitis, including fistulae, abscess formation or
             gastrointestinal perforation

          6. History of allergic reactions attributed to compounds of similar chemical or
             biological composition as tocilizumab, including known allergies to Chinese hamster
             ovary cell products or other recombinant human or humanized antibodies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koen van Besien, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashlee Torres, RN</last_name>
    <phone>212-746-7117</phone>
    <email>ant9015@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>June Greenberg, RN</last_name>
    <phone>212-746-2651</phone>
    <email>jdg2002@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ashlee Torres, RN</last_name>
      <phone>212-746-7117</phone>
      <email>ant9015@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Koen van Besien, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tocilizumab</keyword>
  <keyword>Haplo-Cord Transplant</keyword>
  <keyword>Allogeneic Transplant</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

